Heparin monitoring during extracorporeal circulation;Monitorage de l'héparine durant la circulation extracorporelle

ITBM-RBM

Volumn 24, Issue SUPPL. 1, 2003, Pages

  Belisle S ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Activated clotting time; Cardiopulmonary bypass; Heparin; Point of care monitor

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CONFERENCE PAPER; DRUG EFFICACY; DRUG MONITORING; EXTRACORPOREAL CIRCULATION; HEART SURGERY; MONITOR; THROMBOSIS;

EID: 0346154828     PISSN: 12979562     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. Heimark RL, Fujikawa K, Davie EW. Surface activation of blood coagulation, fibrinolysis and kinin formation. Nature 1980;286:456-60.
2. Boisclair MD, et al. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood 1993;82:3350-7.
3. de Haan J, et al. Retransfusion of suctioned blood during cardiopulmonary bypass impairs hemostasis. Ann Thorac Surg 1995:59:901-7.
4. Belisle S, Hardy JF. Hemorrhage and the use of blood products after adult cardiac operations: myths and realities. [Review] [63 refs]. Ann Thorac Surg 1996;62:1908-17.
5. Beguin S, et al. Conjectures and refutations on the mode of action of heparins. The limited importance of anti-factor xa activity as a pharmaceutical mechanism and a yardstick for therapy. Haemostasis 1999;29:170-8.
6. Esposito RA, et al. Heparin resistance during cardiopulmonary bypass. The role of heparin pretreatment. J Thorac Cardiovasc Surg 1983;85:346-53.
7. Bull BS, et al. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 1975;69:685-9.
8. Cohen M. Monitoring anticoagulation during percutaneous coronary interventions. J Thromb Thrombolysis 1995;1:285-8.
9. Despotis GJ, et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994;108:1076-82.
10. Murray DJ, et al. Heparin detection by the activated coagulation time: a comparison of the sensitivity of coagulation tests and heparin assays. J Cardiothorac Vasc Anesth 1997;11:24-8.
11. Culliford AT, et al. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg 1981;193:105-11.
12. Despotis GJ, et al. Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques. Anesthesiology 1999;91:1122-51.
13. Forestier F, et al. Reproducibility and interchangeability of the Thromboelastograph, Sonoclot and Hemochron® activated coagulation time in cardiac surgery. Can J Anaesth 2001;48:902-10.
14. Dietrich W, Jochum M. Effect of celite and kaolin on activated clotting time in the presence of aprotinin: activated clotting time is reduced by binding of aprotinin to kaolin. J Thorac Cardiovasc Surg 1995;109:177-8.
15. Hattersley PG. Activated coagulation time of whole blood. Jama 1966;196:436-40.
16. Kesteven PJ, et al. Significance of the whole blood activated clotting time in cardiopulmonary bypass. J Cardiovasc Surg (Torino) 1986;27:85-9.
17. Moorehead MT, Westengard JC, Bull BS. Platelet involvement in the activated coagulation time of heparinized blood. Anesth Analg 1984;63:394-8.
18. Despotis GJ, et al. Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation. Anesth Analg 1997;85:498-506.
19. Bull MH, Huse WM, Bull BS. Evaluation of tests used to monitor heparin therapy during extracorporeal circulation. Anesthesiology 1975;43:346-53.
20. Young JA, Kisker T, Doty DB. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and appearance of fibrin monomer. Ann Thorac Surg 1978;26:231-40.
21. Kestin AS, et al. The platelet function defect of cardiopulmonary bypass. Blood 1993;82:107-17.
22. Donias HW, et al. Heparin dose, transfusion rates, and intraoperative graft patency in minimally invasive direct coronary artery bypass. Heart Surg Forum 2003;6:176-80.
23. Hardy JF, et al. Measurement of heparin concentration in whole blood with the Hepcon/HMS device does not agree with laboratory determination of plasma heparin concentration using a chromogenic substrate for activated factor X. J Thorac Cardiovasc Surg 1996;112:154-61.
24. Koster A, et al. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management. Anesthesiology 2002;97:837-41.
25. Gravlee GP, et al. Heparin management protocol for cardiopulmonary bypass influences postoperative heparin rebound but not bleeding. Anesthesiology 1992;76:393-401.
26. Despotis GJ, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation [see comments]. J Thorac Cardiovasc Surg 1995;110:46-54.
27. Hashimoto K, et al. Heparin and antithrombin III levels during cardiopulmonary bypass: correlation with subclinical plasma coagulation. Ann Thorac Surg 1994;58:799-804; discussion 804-5.
28. Dietrich W, et al. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. A double-blind, placebo-controlled study. Anesthesiology 1995;83:679-89; discussion 29A-30A.
29. Paniccia R, et al. Evaluation of a new point-of-care celite-activated clotting time analyzer in different clinical settings. The i-STAT celite-activated clotting time test. Anesthesiology 2003;99:54-9.
30. Hunt BJ, Segal H, Yacoub M. Aprotinin and heparin monitoring during cardiopulmonary bypass. Circulation 1992;86Suppl 5:II410-2.
31. Najman DM, et al. Effects of aprotinin on anticoagulant monitoring: implications in cardiovascular surgery. Ann Thorac Surg 1993;55:662-6.
32. Wendel HP, et al. The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement. Blood Coagul Fibrinolysis 1993;4:41-5.
33. Landis RC, Haskard DO, Taylor KM. New antiinflammatory and platelet-preserving effects of aprotinin. Ann Thorac Surg 2001;72:S1808-13.
34. Huang H, et al. Mechanism of the preserving effect of aprotinin on platelet function and its use in cardiac surgery. J Thorac Cardiovasc Surg, 1993;106:11-8.
35. Landis RC, et al. The antithrombotic and antiinflammatory mechanisms of action of aprotinin. Ann Thorac Surg 2001;72:2169-75.